Last updated: 2026-09-05 00:13:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Sana Biotechnology, Inc. (SANA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $3.85, with a market capitalization of $1.16B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.61 to $6.55. This page covers its latest market performance, valuation, price trends and company information.
$1.16B | |
$3.86 | |
$44.60 | |
$1.26 | |
$3.92 | |
1.07M | |
-- | |
-- | |
$6.55 | |
$2.61 | |
-- | |
-- |
Sana Biotechnology, Inc. (SANA) last closed at $3.92 as of 2026-09-04 23:46:00, unchanged from the previous close of $3.92.
During the latest regular trading session, SANA traded between $1.26 and $44.60, with a volume of 1.07M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Sana Biotechnology, Inc. (SANA) moved from $3.87 to $3.85, representing a decline of 0.65% ($0.02).
The stock traded between $3.81 and $3.96 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1.97 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 31.3%
SANA is currently trading at $3.85, placing it 31.3% of the way from its 52-week low of $2.61 to its 52-week high of $6.55. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 142 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Sana Biotechnology, Inc. (SANA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.